CDC Thinks Exposing Babies To Meningitis is More Cost-Effective Then Immunizing Them

  • by: |
  • 06/21/2012
I'm not making that up..

CDC -- through the Advisory COmmitee on Immunization Practices -- which recommends what vaccines will be covered by the government and health plans under the new health law -- has decided that new vaccines for meningitis that prevents thousands of cases where children are maimed and hundreds of deaths each year isn't worth it.   A study by the Dr. Chris Stomberg of Bates-White Economic Consulting entitled:  Policy Priorities and the Value of Life raises some disturbing questions that Congress should focus on.  

Dr. Stomberg writes:

"In contrast to its Medicare program, the government makes life and death decisions at the other end of the age scale, guided in part by cost considerations. In fact, the CDC has come to explicitly consider cost-effectiveness studies when setting nationwide childhood immunization policy. 

When the first meningococcal vaccine for adolescents (ages 11 to 55) was approved by the FDA in 2005, CDC promptly included it on the routine vaccine schedule. ACIP’s recommendation at that time was supported, in part, by information found in a cost-effectiveness study (Shepard et al. 2005)
that was led by a team of investigators from the CDC and published in the journal Pediatrics.

                                                                   Cases            Deaths        QALYS                  Cost per 
                                                                    Averted         Averted       Gained                  QALY Gained
Adolescent 270 36 1805 138
Toddler 385 33 2793 105
Infant 447 36 3429 271

This study estimated the benefits in terms of deaths averted, cases averted, and QALYs gained if the meningococcal vaccine were administered to three different populations: adolescent, toddler and infant.....the study actually found that the greatest benefits would be accrued by
administering a meningococcal vaccine to the infant population, and the lowest cost per QALY would the fact that prior studies In early 2010, after it reviewed the results of a cost-effectiveness study of meningococcal vaccine for infants, ACIP continued to hold its position against including any of the forthcoming infant vaccines in its routine recommendations once approved by FDA.

In Aril 2011, the FDA approved the first meningococcal vaccine for infants, with other products on the horizon for this age group as well. A
routine recommendation for infant use of meningitis vaccines has not yet been made.What this example highlights is the importance of cost in the CDC’s deliberations over its infant meningitis immunization recommendations. It provides an interesting counterpoint to Medicare’s decision to continue coverage of Avastin. While Medicare has elected to continue covering the use of a drug for which the FDA has withdrawn approval, CDC has refrained from recommending (and paying for) the use of an FDA-approved vaccine. Whether intentional or not, there is apparently a deep divide in how the government thinks about healthcare spending at the two ends of the age spectrum. With no consistent method for evaluating health programs, this is to be expected. "

You can read the entire paper here.

Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog